Get the Stockscreener App
207.11
0.60%
-1.24
After Hours:
207.11
Overview
News
Price History
Option Chain
Financials
Why BDX Down?
Discussions
Forecast
Stock Split
Dividend History
Becton Dickinson Co stock is traded at $207.11, with a volume of 1.57M.
It is down -0.60% in the last 24 hours and up +5.46% over the past month.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.
See More
Previous Close:
$208.35
Open:
$207.075
24h Volume:
1.57M
Relative Volume:
0.73
Market Cap:
$59.01B
Revenue:
$21.84B
Net Income/Loss:
$1.68B
P/E Ratio:
35.53
EPS:
5.8293
Net Cash Flow:
$2.67B
1W Performance:
+2.15%
1M Performance:
+5.46%
6M Performance:
+16.18%
1Y Performance:
-12.35%
1-Day Range:
$206.65
$209.12
1-Week Range:
$198.44
$209.27
52-Week Range:
$162.29
$251.99
Becton Dickinson Co Stock (BDX) Company Profile
Name
Becton Dickinson Co
Sector
Industry
Phone
(201) 847-6800
Address
ONE BECTON DR, FRANKLIN LAKES
Compare BDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
207.11 | 59.36B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ISRG
Intuitive Surgical Inc
|
535.00 | 191.90B | 9.61B | 2.77B | 2.27B | 7.555 |
|
ALC
Alcon Inc
|
79.00 | 39.13B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
257.58 | 38.05B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
44.12 | 33.62B | 27.43B | 1.27B | 1.01B | 1.5829 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | RBC Capital Mkts | Sector Perform |
| May-22-25 | Downgrade | Citigroup | Buy → Neutral |
| May-02-25 | Downgrade | Goldman | Buy → Neutral |
| May-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-01-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-24-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| May-05-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-12-23 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jan-03-23 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-22 | Upgrade | Citigroup | Sell → Neutral |
| Jul-11-22 | Downgrade | Citigroup | Neutral → Sell |
| Jun-24-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-18-22 | Resumed | Raymond James | Mkt Perform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Dec-08-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-09-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-01-20 | Resumed | Goldman | Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-07-20 | Downgrade | Cowen | Outperform → Market Perform |
| Feb-07-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Feb-07-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Feb-06-20 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-08-20 | Downgrade | Barclays | Overweight → Equal Weight |
| May-13-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-07-18 | Initiated | Deutsche Bank | Buy |
| Oct-16-18 | Initiated | Barclays | Equal Weight |
| Jun-21-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Jan-19-18 | Resumed | BofA/Merrill | Buy |
| Jan-05-18 | Upgrade | Citigroup | Sell → Neutral |
| Jan-05-18 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Dec-29-17 | Reiterated | Deutsche Bank | Buy |
View All
Becton Dickinson Co Stock (BDX) Latest News
Becton Dickinson EVP Garrison sells $334,005 in BDX stock - Investing.com India
Atherectomy Devices Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036 - GlobeNewswire Inc.
BD secures FDA 510(k) clearance for EnCor EnCompass system - Yahoo
Lobbying Update: $1,496,000 of BECTON DICKINSON AND COMPANY lobbying was just disclosed - Quiver Quantitative
Becton, Dickinson Wins FDA Clearance For Next-Gen Breast Biopsy Device, Launch Set For 2026 - Benzinga
BD receives FDA clearance for new breast biopsy system By Investing.com - Investing.com India
BD Receives FDA 510(k) Clearance for EnCor EnCompass Breast Biopsy and Tissue Removal System - Finviz
Manning & Napier Advisors LLC Sells 29,843 Shares of Becton, Dickinson and Company $BDX - MarketBeat
FDA clears new BD device aimed at improving breast biopsies for patients - Stock Titan
Becton, Dickinson and Company $BDX Shares Sold by Pacific Capital Partners Ltd - MarketBeat
BD Names Shawn Bevec as Senior Vice President of Investor Relations - Finviz
BD Names Shawn Bevec as Senior Vice President of Investor Relations – Company Announcement - Financial Times
Sumitomo Mitsui Trust Group Inc. Increases Stock Position in Becton, Dickinson and Company $BDX - MarketBeat
Is Becton Dickinson (BDX) Pricing Reflect Its Recent Multi‑Year Share Price Declines - Yahoo Finance UK
Assessing Becton Dickinson (BDX) Valuation After Recent Share Moves And Business Separation Plans - Yahoo Finance
BD Announces $110M Investment - citybiz
BD (BDX) Invests $110M to Enhance Syringe Production in Nebraska - GuruFocus
S Bank Fund Management Ltd Raises Holdings in Becton, Dickinson and Company $BDX - MarketBeat
BD Announces $110 Million to Support U.S. Pharmaceutical Supply Chain for Biologic Drugs - Finviz
Becton Dickinson’s Strategic Pivot Enters Critical Phase - AD HOC NEWS
Nebraska plant gets $110M boost to make syringes for new biologic drugs - Stock Titan
Sterilization Services MarketGlobal Forecast 2025-2032: Coverage of B. Braun, Becton Dickinson, Belimed, Cardinal Health, Ecolab, STERIS, and Sotera Health - Yahoo Finance UK
Hardman Johnston Global Advisors LLC Decreases Stock Holdings in Becton, Dickinson and Company $BDX - MarketBeat
Oregon Public Employees Retirement Fund Purchases 8,019 Shares of Becton, Dickinson and Company $BDX - MarketBeat
Robeco Institutional Asset Management B.V. Cuts Holdings in Becton, Dickinson and Company $BDX - MarketBeat
Waters and Biosciences & Diagnostic Solutions unit to combine for $17.5B - MSN
Why We're Not Concerned About Becton, Dickinson and Company's (NYSE:BDX) Share Price - 富途牛牛
HB Wealth Management LLC Grows Holdings in Becton, Dickinson and Company $BDX - MarketBeat
Becton, Dickinson and Company $BDX Shares Sold by Cerity Partners LLC - MarketBeat
RBC Capital Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Maintains Target Price $210 - 富途牛牛
Is BD (BDX) Quietly Recasting Its Surgical Innovation Story With Expanded Phasix Mesh Use in Europe? - simplywall.st
Is Becton Dickinson and Company (BOX) stock a top hedge fund pickJuly 2025 Pullbacks & Free Expert Approved Momentum Trade Ideas - ulpravda.ru
What to Expect From Becton, Dickinson and Company's Next Quarterly Earnings Report - Barchart.com
SG Americas Securities LLC Acquires 76,233 Shares of Becton, Dickinson and Company $BDX - MarketBeat
KLP Kapitalforvaltning AS Sells 31,300 Shares of Becton, Dickinson and Company $BDX - MarketBeat
Benjamin Edwards Inc. Increases Stake in Becton, Dickinson and Company $BDX - MarketBeat
Stifel raises Becton Dickinson stock price target to $215 from $210 - Investing.com Nigeria
Becton Dickinson (BDX): Stifel Raises Price Target to $215 | BDX Stock News - GuruFocus
Stifel raises Becton Dickinson stock price target to $215 from $210 By Investing.com - Investing.com South Africa
Stifel Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Raises Target Price to $215 - 富途牛牛
The Truth About Becton Dickinson and Co (BDX): Quiet Healthcare Giant, Loud Money Moves - AD HOC NEWS
Becton, Dickinson and Company (BDX) Announces Blackout Period fo - GuruFocus
Becton Dickinson announces temporary blackout period for 401(k) plan stock fund - Investing.com Nigeria
Becton Dickinson & CoOn Dec 30, Bd 401(K) Plan to Enter Blackout Period Due to Waters DealSEC Filing - TradingView — Track All Markets
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
Mcdaniel Terry & Co. Sells 74,357 Shares of Becton, Dickinson and Company $BDX - MarketBeat
Becton, Dickinson and Company $BDX Shares Bought by D.A. Davidson & CO. - MarketBeat
RBC sees durable growth profile at Becton Dickinson (BDX), raises target - MSN
Becton Dickinson & Co. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
BDX: B of A Securities Raises Becton Dickinson's Price Target | - GuruFocus
BofA Securities Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Raises Target Price to $207 - 富途牛牛
Becton Dickinson Co Stock (BDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
3.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):